Drug Delivery and Translational Research - Featured Article: October 2022
Read the featured article from the October 2022 issue! (this opens in a new tab)
Summary
Systemic Injection of polyethylene glycol (PEG)-modified nanomedicines can promote accelerated clearance of the next dose of PEGylated nanomedicines via the accelerated blood clearance (ABC) phenomenon. It has been reported the interface between the PEG chain and the hydrophobic segment is the primary binding site recognized by anti-PEG IgM and responsible for increasing the liver uptake and shortening the circulation time of PEGylated nanomedicines. In this study, we demonstrate that the 1,2-distearoyl-snglycero-3-phosphoglycerol (DSPG) in PEGylated nanoemulsions (PEs) may mask this interface, thereby inhibiting the recognition and binding of PEs by anti-PEG IgM and weakening the ABC phenomenon of PEs. This finding provides a novel strategy to improve the pharmacokinetics and ultimately therapeutic efficacy of PEGylated nanocarriers.